Original Article

Expression analysis of BORIS during pluripotent, differentiated, cancerous, and non-cancerous cell states

Sara Soltanian1,2, Hesam Dehghani3,4*, Maryam M. Matin1,2, and Ahmad Reza Bahrami1,2

1Department of Biology, Faculty of Science, Ferdowsi University of Mashhad 91779-48974, Mashhad, Iran
2Cell and Molecular Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad 91779-48974, Iran
3Department of Basic Sciences, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad 91779-48974, Iran
4Embryonic and Stem Cell Biology and Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad 91779-48974, Mashhad, Iran

*Correspondence address. Tel: +98-(511)-880-5613; Fax: +98-(511)-876-3852; E-mail: dehghani@um.ac.ir

BORIS/CTCFL is an 11 zinc finger protein, which is the paralog of CTCF, a ubiquitously expressed protein with diverse roles in gene expression and chromatin organization. Several studies have shown that the expression of BORIS is restricted to normal adult testis, pluripotent cells, and diverse cancer cell lines. Thus, it is known as a cancer-testis (CT) gene that has been hypothesized to exhibit oncogenic properties and to be involved in cancer cell proliferation. On the contrary, other reports have shown that its expression is more widespread and can be detected in differentiated and normal somatic cells; hence, it might have roles in general cellular functions. The present study was aimed to analyze the expression of BORIS in different cell states of pluripotent, differentiated, cancerous and non-cancerous. We found that the two cell states of pluripotency and differentiation are not accompanied with significant variations of BORIS expression. Furthermore, Boris transcripts were detected at approximately the same level in cancer and non-cancer cell lines. These findings suggest that, in contrast to some previous reports, the expression of mouse BORIS is not limited to only cancerous cells or pluripotent cell states.

Keywords BORIS; differentiation; cancer; embryonal carcinoma P19 cells; retinoic acid

Received: February 27, 2014 Accepted: April 8, 2014

Introduction

Brother of the regulator of the imprinted site (BORIS) or CCCTC-binding factor-like protein (CTCFL) is an 11 zinc finger (ZF) protein, described as a transcriptional regulator. BORIS is a paralog of CCCTC-binding factor (CTCF), a protein that has been called the ‘master weaver of the genome’ [1–3]. BORIS exhibits high homology with CTCF in the central 11 ZF DNA binding domains, so it is thought to act as an antagonist to CTCF in normal and cancer cells by binding to the same target sequences [1]. Despite the high homology of central domains in CTCF and BORIS, the flanking N- and C-terminal domains show very little sequence homology, implying that BORIS and CTCF may recruit different cofactors and lead to various cellular outcomes [3–5].

BORIS was originally found in male germ cells, particularly in primary spermatocytes and round spermatids within the normal testis [4]. In addition, significant expression of BORIS was also detected in tumors and cancer cell lines [6–19]. The majority of these reports did not find the expression of BORIS in other normal somatic tissues and cells [4,6,8–10,18,20]. Thus, the expression of BORIS was viewed as an aberrant phenomenon in cancer, and its expression in testis and many cancers led to its classification as a cancer-testis (CT) gene [1,8,16,17]. In a few studies, BORIS expression was also detected in some pluripotent cells including human embryonic stem (hES) [18,21] and embryonal carcinoma (EC) cells (TERA-1, TERA-2, NTERA2, and NCCIT) [15]. These reports suggested a possible link between the state of pluripotency (undifferentiated) and BORIS expression. A pluripotent and an undifferentiated state in tumor cells may lead to self-renewal, high proliferative capacity, immortality, and phenotypic plasticity [22–25]. In fact, the stem cell-like phenotypes including the expression of pluripotent marker genes especially those associated with reprogramming, the undifferentiated and proliferative stem cell state, and also the maintenance of that state (accompanied by the expression of OCT4, SOX2, KIF4, and c-MYC) have been detected in cancer cells, especially in poorly differentiated aggressive tumors [26–39]. These evidence suggest that the acquisition of a stemness state, an important phase towards cancer [40], and the expression of BORIS might be interrelated. According to these reports, BORIS in cancer-pluripotent cells might replace CTCF on the regulatory regions of CT genes (e.g. Oct4 and some members of MAGE-A family genes), oncogenes (e.g. c-Myc), and...
hTERT promoter to disturb a silenced gene state and to lead to the proliferation of cancer cells [1,4,6,10,11,14,41–44].

On the contrary, the expression of BORIS cannot be detected in some cancer cell lines or tumors [10,12,15–17,45,46], and has also been detected in several mouse and human somatic tissues and non-cancerous cell lines [17,46,47]. This may point to the widespread expression of BORIS which is not restricted to cancerous cell lines. In addition, it has been found that the expression of some CT genes does not rely on the presence of BORIS [12,17,48,49], and thus, it is unlikely that BORIS would be a major CT gene inducing factor [50]. Furthermore, some more general biological functions including a regulatory role in normal cell division have been proposed for BORIS [47], which leads to a significant decrease in cell proliferation and clonogenic capacity. These growth inhibitory functions categorize BORIS as a candidate tumor suppressor gene, rather than an oncogene [20].

Reports indicating the expression of BORIS in cancer-pluripotent cells on one hand, and studies showing the widespread expression and function of BORIS in normal cells and tissues on the other hand, prompted us to identify whether the expression of this gene is restricted to a specific cell state, pluripotency vs. differentiated, and cancerous vs. non-cancerous. To this point in P19 cells, we quantified the level of BORIS during an undifferentiated pluripotent state (EC cells), in early differentiated retinoic acid (RA)-induced 4-day old embryoid bodies (EBs) (EB4), and in fully differentiated EBs (4 days after transfer to tissue culture plates in RA-free medium; EB-D4). In addition, we also quantified Boris in mouse cancer (CT26, N2A) and non-cancer (3T3, STO) cell lines. Along with the expression of BORIS, we also identified some pluripotency-associated factors [OCT4, NANOG, SSEA1, and alkaline phosphatase (AP)], and several differentiation markers (GATA-4, Tubulin βIII, NeuN, and Neurofilament 200). We found that the expression of BORIS does not show a significant change during the differentiation of P19 cells. In addition, Boris transcript was detected in both cancer (N2A and CT26) and non-cancer (STO) cell lines at approximately the same level. These findings indicate that a pluripotency state in either cancer or pluripotent cells may not be related to the level of BORIS expression and that the expression of BORIS is not altered due to the cancerous or non-cancerous state of the cells.

Materials and Methods

Culture and induction of differentiation of P19 cells
P19, STO, 3T3, N2A, and CT26 cells were obtained from Pasteur Institute (Tehran, Iran). P19 cells are EC pluripotent cells with the ability to differentiate to derivatives of three germ layers in response to different chemical inducers and culture conditions [51,52]. In response to RA treatment and EB formation, P19 cells lose their pluripotency rapidly, as evidenced by the decreased expression of pluripotent stem cell markers [53–55] and differentiate into neurons, glial, and fibroblast-like cells [56,57]. P19 cells were cultured in minimum essential medium eagle, alpha modification (α-MEM; Sigma-Aldrich, Munich, Germany) and STO, 3T3, N2A, and CT26 cells were cultured in Dulbecco’s modified Eagle’s medium (Gibco, Grand Island, USA). Both media were supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (Gibco). All the cell lines were incubated at 37°C in a 5% CO₂ atmosphere.

For RA-induced differentiation of P19 cells, aggregates were formed by placing 0.2 × 10⁶ cells into 8 cm diameter bacteriological grade petri dishes containing 8 ml of complete α-MEM medium supplemented with 0.5 μM RA (Sigma, Munich, Germany). After 2 days incubation, the medium was replenished with fresh RA-containing medium [57] and cells were cultured for two more days. EB4 were dissociated by trypsinization and their viability was assayed by trypan blue exclusion assay. For neurodifferentiation, EB4 aggregates were plated onto tissue culture grade surfaces in medium lacking RA and were cultured for additional 4 days (EB-D4). Media were replaced every 48 h [56]. RA was prepared as 10⁻² M stock solutions in ethanol and was diluted directly into the culture medium to obtain the desired concentration. In this work, undifferentiated P19 cells, EB4, and the EB-D4 cells were studied.

AP staining
To detect AP activity in P19 cells and its alteration after RA treatment, P19 cells were grown on coverslips and were fixed with 4% paraformaldehyde (PFA; Sigma) in phosphate-buffered saline (PBS) for 10 min. For AP staining of aggregates (EB4), by using a plugged Pasteur pipette, an individual aggregate was transferred on the center of gelatin-coated glass coverslip placed in each well of a six-well tissue culture plate. To avoid dislodging the cells from the surface, 2 ml medium was added to each well. Incubation for a few hours allowed aggregates to attach to the gelatin surface. To investigate AP activity on mature differentiated cells (EB-D4), after 4 days in suspension, aggregates were transferred and cultured on the center of coverslips for 4 days in RA-free medium. Cells cultured on coverslips were fixed with 4% PFA. After fixation, each coverslip was washed three times with AP buffer (100 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl₂, 0.05% Tween-20, pH 9.5, all from Merck, Ballerup, Denmark), and then was covered with 1 ml of AP solution prepared by mixing 120 ml of 1% 5-bromo-4-chloro-3-indolyl phosphate (Fluorescent, Schwerte, Germany) in 100% dimethylformamide (DMF; Merck), 120 ml of 1.5% nitroblue tetrizolium (Fluorescent) in 70% DMF, and 5 ml of AP buffer. After 15 min, coverslips were washed with AP buffer, then mounted on the slide with the application of 40 μl antifade, and observed under an Olympus BX-UCB microscope (Olympus, Tokyo, Japan).
Immunocytochemistry

Immunocytochemistry (ICC) was used to detect the presence of pluripotency and neural cell-specific proteins. Cells were fixed as described for AP staining. After fixation and washing with PBS (three times, 5 min each), cells were permeabilized with Tris-buffered saline containing 0.5% Triton X-100 (Merck) for 10 min at room temperature (RT). Cells were then washed with PBS (three times, 5 min each) and endogenous peroxidase was blocked by incubating in 3% H2O2 (Sigma) in PBS for 30 min. After washing with PBS, blocking of non-specific binding was performed by incubation in 4% (v/v) bovine serum albumin (BSA; Invitrogen, Grand Island, USA) for 45 min. Cells were then incubated with the specific primary antibodies: mouse anti-BORIS (Cat. No. 061502E05, 1:50; Abseia Biotechnology Ltd, Beijing, China), mouse anti-OCT4 (Cat. No. sc-5279, 1:100; Santa Cruz Biotechnology, Inc., Heidelberg, Germany), mouse anti-NANOG (Cat. No. sc-293121, 1:500; Santa Cruz Biotechnology, Inc.), mouse anti-SSEA1 (Cat. No. sc-101462, 1:100; Santa Cruz Biotechnology, Inc.), and rabbit anti-Neurofilament 200 (Cat. No. N4142, 1:100; Sigma-Aldrich) in blocking buffer (1% BSA) overnight at 4°C. Then, cells were washed with PBS (three times, 10 min each) and were incubated for 1 h at RT with secondary antibodies specific for each primary antibody: goat anti-rat IgG-HRP (Cat. No. sc-2065, 1:500; Santa Cruz Biotechnology, Inc.), goat anti-mouse IgG2b-HRP (Cat. No. ab97250, 1:500; Abcam, Cambridge, UK), goat anti-mouse IgG1-HRP (Cat. No. ab97240, 1:1000; Abcam), rat anti-mouse IgM-HRP (Cat. No. 04-6820, 1:1500; Invitrogen), and donkey anti-rabbit IgG-HRP (Cat. No. sc-2317, 1:500; Santa Cruz Biotechnology, Inc.). Finally, cells were washed for several times with PBS and stained with 3,3′-diaminobenzidine (Cat. No. D8001; Sigma-Aldrich) at RT for 2 min. After washing with PBS, coverslips were mounted on the slide with the application of 40 μl antifade and were analyzed under the Olympus BX-UCB microscope. Negative controls were stained with only the secondary antibodies.

RNA extraction and cDNA synthesis

Total RNA was isolated using Total RNA isolation kit (DENAzist Asia, Mashhad, Iran) according to the manufacturer’s guidelines. The quantity and quality of RNA were assessed using a Nanodrop 2000 spectrophotometer (Thermo Scientific, Wilmington, USA) and agarose gel electrophoresis (Supplementary Fig. S1).

Possible contaminating genomic DNA was removed by DNase I treatment. For DNase I treatment, 10–50 μg of total RNA was digested for 15 min at RT with 1 μl (10 U/μl) of DNase I (Roche, Penzberg, Germany) and 1 × DNase I reaction buffer in a 50 μl reaction volume. First-strand cDNA was prepared in a total volume of 20 μl containing 1 μg total RNA, 0.5 μg Oligo(dT)18 primer (Thermo Scientific), 1 × RT buffer (Thermo Scientific), 1 mM dNTPs (Genet Bio, Inc., Daejeon, Korea), and 200 U of reverse transcriptase (Thermo Scientific). The reaction was incubated at 42°C for 60 min. Negative control reactions were carried out without the use of reverse transcriptase.

Polymerase chain reaction

The polymerase chain reaction (PCR) mixture (25 μl) contained 1 μl of template cDNA, 0.04 U of Taq DNA polymerase (Genet Bio, Inc.), 1 × PCR buffer, 1.5 mM MgCl2, 0.2 mM dNTPs, and 200 nM of each primer. The number of PCR cycles in semi-quantitative reverse transcription-PCR (RT-PCR) has been adjusted for each gene to prevent reaching a saturation level and normalization with respect to L37 cDNA allows to estimate the relative abundance of each target mRNA. Primers for L37, Oct4, Nanog, Gata-4, NeuN, and Boris were chosen from different intron-spanning exons. All primers were the same for both conventional and real-time quantitative PCR (qPCR). All specific primers are described in Table 1 and Supplementary Fig. S2.

Quantitative real-time RT-PCR

To quantify the level of transcripts for Oct4, Nanog, and Boris, quantitative RT-PCR was performed. The reactions contained 1 × SYBR Green Real-time PCR Master Mix (Pars Tous, Mashhad, Iran), 2 μl diluted cDNA template and each primer at 250 nM in a 20 μl reaction volume, which was carried out on a CFX-96 Thermalcycler (Bio-Rad, Hercules, USA). Gene-specific primers were designed using Oligo7 Primer Analysis Software. Amplification conditions for Oct4, Nanog, and L37 were: 95°C for 10 min, followed by 40 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s. Plate read step to collect fluorescence for mentioned genes was at 72°C. The same program was used for Boris except that annealing temperature was 62°C and there was an extra step of 78°C for 10 s to collect fluorescence at a temperature above the melting point of any possible primer dimers. At the end of the PCR runs to derive melting curves, temperature was increased in steps of 1°C for 10 s from 60°C to 95°C.

Analysis of melting curves clearly indicated that each of the primer pairs described in Table 1 amplified a single expected product with a distinct expected product with a distinct Tm (Supplementary Fig. S3). The accuracy of the amplification reaction was validated by gel electrophoresis and restriction digestion of PCR products (Supplementary Fig. S4) and sequencing.

For undifferentiated P19 cells and each stage of differentiated cells (EB4 and EB-D4), three biological replicates were considered. Three series of isolated RNAs were subjected to cDNA synthesis and qPCR. For each sample, qPCR readings were performed in triplicate and the mean value of each triplicate was used for the calculation of the mRNA expression levels. To acquire the highest level of accuracy, the real-time PCR analyses were performed in two series of experiments.
PCR efficiencies ($E$) were calculated for all used primers from the given slopes of standard curves, generated using 5 fold serially diluted solutions of positive control cDNA samples, according to the following equation:

$$E = \frac{\left(10^{-\frac{1}{2}}\right)}{\text{slope}^2} \times 100\%.$$ Positive control for Boris expression was mouse testis, and P19 cells were used as a positive control for L37, OCT4, and Nanog. All standard curves were linear in the analyzed range with an acceptable correlation coefficient ($R^2$). For standard curves and parameters of a standard curve for each gene see Table 2 and Supplementary Fig. S5.

In this study, the variability of L37 transcript levels was evaluated before and after RA treatment by real-time PCR. The mean threshold cycle ($C_T$) of L37 was similar in undifferentiated P19 cells, EB4, and EB-D4 (Supplementary Fig. S6). Therefore, we found L37 as a suitable internal control in these experiments.

**Table 1. Primers used in RT-PCR and real-time qPCR**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer sequence (5' → 3')</th>
<th>Annealing temperature (°C)</th>
<th>Product length (bp)</th>
</tr>
</thead>
</table>
| POU domain, class 5, transcription factor 1 (Oct4) | F: CTCTGAGCCCTGTGCCGACC  
R: CTGAACACCTTCCAAGAAGAAGC | 60                         | 202                  |
| Nanog homeobox (Nanog)      | F: GAACCTTCCTTCCATCTGAACCTG  
R: GGTTGCTAGCCCTTCTGAATC | 60                         | 137                  |
| CCCTC-binding factor (ZF protein)-like (Cctfl) (Boris) | F: ACCTGAGGAAGTACCATGACCAGA  
R: TTGTGTCCTGCTTCCCCTCCTCGAG | 62                         | 196                  |
| Ribosomal protein L37 (Rpl37) | F: GGTGCTTTTCTCTCGGCTCT  
R: TCTTATGTGCTCTCATCCGACCAG | 60                         | 250                  |
| GATA binding protein 4 (Gata-4) | F: GAAAACCGAAGCAGCCAAGACC  
R: TGCTGTGCCCATAGTGAATGAC | 58                         | 186                  |
| Tubulin, beta 3 class III (Tubb3) | F: CGTCCGGCCGTGCTTTCGCG  
R: TAGGGTCCACACAGTGTCC | 67                         | 589                  |
| Fox-1 homolog (Caenorhabditis elegans) 3 (Rhfo3) (NeuN) | F: CAACATCCCCCTCCGGTCC  
R: TGACCTCAATTTCCTCGGCC | 59                         | 200                  |

**Table 2. Evaluation of parameters of a standard curve for each gene**

<table>
<thead>
<tr>
<th>Target</th>
<th>Slop</th>
<th>$R^2$</th>
<th>Efficiency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>L37</td>
<td>-3.315</td>
<td>0.996</td>
<td>100.2</td>
</tr>
<tr>
<td>OCT4</td>
<td>-3.308</td>
<td>0.993</td>
<td>100.5</td>
</tr>
<tr>
<td>NANOG</td>
<td>-3.320</td>
<td>0.990</td>
<td>100.0</td>
</tr>
<tr>
<td>BORIS</td>
<td>-3.330</td>
<td>0.991</td>
<td>101.0</td>
</tr>
</tbody>
</table>

Efficiency = ($10^{-\frac{1}{2}}\text{slope} - 1) \times 100\%$.

**Comparative C_T method for relative quantification**

This method is applied when amplification efficiencies of the target and reference genes are similar and close to 100%. Since our results met these criteria, we analyzed our qPCR data using this method, too. This analysis method involves a calculation known as the Delta Delta $C_T$ ($\Delta \Delta C_T$), which is based on a $C_T$ number comparison between the target gene and the reference gene relative to a calibrator. The data were analyzed using the following equation [60]:

$$\text{Relative quantity} = 2^{-\Delta \Delta C_T}$$

$$\Delta \Delta C_T = (C_T, \text{Target gene} - C_T, \text{Reference gene})_{\text{Test sample}}$$

$$- (C_T, \text{Target gene} - C_T, \text{Reference gene})_{\text{Calibrator sample}}$$

The fold change in the target gene relative to the calibrator sample was calculated for each sample using the above-mentioned equation.
**Western blot analysis**

Western immunoblotting was used to verify specificity of anti-mouse BORIS antibody. For this test, mouse testis tissue was used as a positive control for BORIS expression. Testis tissue was immediately frozen in liquid nitrogen, homogenized with a mortar and pestle, and then suspended in lysis buffer [50 mM Tris-HCl, 5 mM ethylenediaminetetraacetic acid, 2% sodium dodecyl sulfate (SDS)]. After incubation on ice, lysate was centrifuged (13,000 g, 15 min) and supernatants were collected. Tissue lysates were heated at 95°C for 5 min, resolved by SDS–polyacrylamide electrophoresis and then transferred to polyvinylidene difluoride membranes. Membranes were incubated in a blocking solution containing 5% dry milk and 0.1% Tween-20 in PBS (overnight at 4°C) and then with primary mouse anti-BORIS antibody (Cat. No. 061502E05, 1 : 1000) for 1 h at RT. Antibody binding was revealed by incubation with goat anti-rat IgG-HRP (Cat. No. sc-2065, 1 : 10,000) for 1 h at RT. The ECL Plus immunoblotting detection system (GE Healthcare Biosciences, Buckinghamshire, UK) was used to detect HRP activity on a chemiluminescence detector system (G Box; Syngene, Cambridge, England).

**Flow cytometry**

To examine the expression of BORIS as an intracellular antigen by flow cytometry (FCM), the following protocol was employed. Cells were dissociated with trypsin and then washed by centrifugation with washing buffer (PBS and 5% FBS). Cells were then fixed with 4% PFA and permeabilized with 0.5% Triton-X-100. After two washing, cells were incubated with diluted primary mouse anti-BORIS antibody (Cat. No. 061502E05, 1 : 50) for 45 min on ice and washed twice with washing buffer. Cells were then incubated with goat anti-rat IgG secondary antibody conjugated to Alexa Fluor® 546 (Cat. No. A-11081, 1 : 150; Life Technologies, Grand Island, USA) for 45 min on ice. At the end of the procedure, unbounded antibodies were removed by two times washing. Finally, cells were suspended in 0.5 ml of washing buffer and then analyzed by FACS callibur (BD Biosciences, San Jose, CA, USA). Negative control was incubated with the secondary antibody only.

**Statistical analysis**

Statistical analyses were carried out by one-way analysis of variance and paired t-test using SPSS version 11 software. Results were reported as mean ± SD and P < 0.05 was considered to be statistically significant.

**Results**

**BORIS expression remains unchanged during RA-induced differentiation of P19 cells**

Culture of EC P19 cells in non-tissue culture plates (bacterial petri dishes) in the presence of RA for 4 days resulted in the formation of tight rounded aggregates (EB4) (Fig. 1A,B) [56,61,62]. By plating EB4 aggregates on tissue culture dishes in a medium lacking RA, within 24 h fibroblast-like cells migrated out of the periphery of EB4 and attached to the dish. After 4 days of plating, neuron-like cells (EB-D4) appeared and grew rapidly over fibroblast-like cells (Fig. 1C,D) [52,56,57,63,64]. Oct4 transcript level in RA-induced differentiated cells (EB4 and EB-D4) was <5% of that in untreated P19 cells (Fig. 2A) and transcription of Nanog showed 81% and 87% decrease in EB4 and EB-D4, respectively (Fig. 2B). In contrast to the sharp decrease in the expression of pluripotency genes during RA-induced differentiation, the transcription of Boris did not alter significantly (Fig. 2C). Two methods of relative quantification of transcript levels based on standard curve and comparative Ct resulted in similar results (Table 3).

Loss of pluripotency in P19 cells in response to RA treatment was also evident at protein level by the decreased expression of pluripotency markers and up-regulation of differentiation markers [52,53]. OCT4 and NANOG are well-known pluripotency genes that are required to maintain the pluripotency and self-renewal of pluripotent cells [65–68]. These two markers and SSEA1 that are highly expressed in pluripotent mouse EC cells (including P19 cells) were rapidly down-regulated at protein level during RA-induced differentiation (Fig. 3 and Supplementary Fig. S7) [53,55,69–72]. Down-regulation of OCT4 was also shown by western blotting (Supplementary Fig. S8A). In addition, the AP activity of undifferentiated P19 cells was also decreased during differentiation (Supplementary Fig. S9) [53,54,73,74]. In EBs,
pluripotent markers are expressed in the outer differentiated cells and a few undifferentiated EC cells that are localized in the inner core. Differentiation of P19 cells into endoderm and neuron cells was further confirmed by over-expression of differentiation markers including Gata-4 (endoderm) [75], Tubulin βIII (ectoderm), NeuN (ectoderm), and Neurofilament (neuron intermediate filament) (Fig. 4) [54,56,76–84].

Expression of BORIS protein was detected in undifferentiated and differentiated P19 cells (EB4 and EB-D4) by ICC (Fig. 5). For quantitative analysis, expression of BORIS was also characterized by FCM. Almost 74% of undifferentiated P19 cells were BORIS positive (Fig. 6A). Similar results were obtained with EB-D4 (Fig. 6B). Therefore, differentiation did not significantly alter the number of BORIS-positive cells. Although the antibody used in this investigation was previously characterized for their specificity for BORIS [85], we verified specificity of BORIS antibody by western blotting, where a densely stained band of 70 kDa in mouse testis corresponded to theoretical molecular weight of mouse BORIS (Supplementary Fig. S8B).

BORIS expression in cancer and non-cancer mouse cells
Real-time RT-PCR analysis to compare the transcript levels of Boris in mouse cancer (CT26 and N2A) and non-cancer (STO and 3T3) cell lines revealed that except in 3T3 cells (with the highest level of expression), all other examined cell lines have similar levels of Boris mRNA (Fig. 7A). Testis as a positive control showed the highest level of Boris mRNA as previously described [4], while primary cell culture of mouse embryonic fibroblasts (MEFs) showed no expression of BORIS at mRNA and protein levels (Fig. 7A,F). Immunocytochemical staining of CT26, N2A, STO, and 3T3 cell lines revealed BORIS expression at protein level (Fig. 7B–E).
Our findings reveal that: (i) the expression level of BORIS does not significantly change during differentiation of pluripotent mouse EC P19 cells, and (ii) Boris is expressed in cancer and non-cancer cell lines at approximately the same level. Therefore, the expression of this gene is not limited to cancer or pluripotent cells. Quantitative expression analysis of BORIS during RA-induced differentiation of pluripotent P19 cells did not show any significant variation at mRNA and protein levels (Figs. 2C and 6) and immunostaining of BORIS in undifferentiated P19 cells, EB4, and EB-D4 showed expression of BORIS in both pluripotent and differentiated cells (Fig. 5). Therefore, down-regulation of pluripotent markers during RA-induced differentiation of pluripotent P19 cells does not lead to down-regulation of BORIS. In another research with similar results, it has been found that BORIS protein is co-localized with OCT4 and NANOG proteins in the nucleus of the majority of ES cells, and it continues to be expressed by some of the differentiating ES cells that have lost the expression of these two genes [21].

In our experiments, the loss of pluripotency marked by down-regulation of pluripotency markers (i.e. OCT4, NANOG, SSEA1, and AP) and differentiation into endoderm–neural lineage evidenced by elevated expression of differentiation markers (i.e. Gata-4, NeuN, Tubulin βIII, and Neurofilament 200). Our RT-qPCR results showed that during RA induction, transcript level of Oct4 and Nanog dropped to <5% and 20% of those in untreated P19 cells, respectively (Fig. 2A,B). Furthermore, the ICC expression analysis showed down-regulation of pluripotency markers (e.g. OCT4, NANOG, SSEA1, and AP) in RA-induced EBs (EB4 and EB-D4) (Fig. 3, Supplementary Figs. S7 and S10) and expression of neuron-specific marker Neurofilament 200 in EB-D4 (Fig. 4D,E). It is well documented that NANOG and OCT4 which are required to maintain the pluripotency and self-renewal of pluripotent cells [65,66,71,86–88], become down-regulated during RA-induced differentiation of pluripotent cells [53,55,71,89–91]. SSEA1 and AP are also two cell surface markers of mouse pluripotent cells that are down-regulated during differentiation [53,54,74].

RT-qPCR analyses in a series of cancer (CT26 colon carcinoma and N2A Neuroblastoma) and non-cancer (STO and 3T3 fibroblasts) cell lines showed that except in 3T3 cells that express the highest level of Boris, all other examined cell lines have similar levels of Boris mRNA, indicating that the state of cancerous or non-cancerous is not a determining factor for the level of Boris expression (Fig. 7). Several reports indicated that the expression of BORIS is not dependent on the cancerous or non-cancerous nature of cells and tissue. For example, although BORIS has been classified as a CT antigen, but new findings in melanoma, ovarian, prostate, breast, head and neck squamous cell carcinomas, and bladder carcinomas [12,15–17,46] have shown that BORIS expression may not directly correlate with tumorigenicity. These studies reported that Boris expression in primary melanomas (27%) is not as frequent as originally estimated for melanoma cell lines (90%) [17], and when measured quantitatively, levels in tumors were not statistically different from those in normal prostate, bladder, and ovarian tissues [15,16]. The elevated
expression of BORIS in several breast cancer cell lines and in the majority of primary breast tumors identified in one study has not been confirmed by another report [8,45]. Furthermore, some researchers have shown the expressions of different Boris isoforms in some normal tissues (e.g. skin, colon, kidney, ovary, fetal tissues, etc.) and non-cancer cells from various origins [4,17,18,46,47,92]. In agreement with the previous reports [6,8,10,20], we also found that BORIS is not expressed in primary-derived MEFs (Fig. 7). Primary cells such as MEFs have limited lifespan. After a certain number of population doublings, cells undergo the process of senescence and stop dividing. Therefore, they would normally not proliferate indefinitely. On the contrary, immortalized cell lines (e.g. STO, 3T3, CT26, and N2A) that undergo many rounds of cell division and probably chromosomal abnormalities. Therefore, we speculate that BORIS might be expressed in all type of cell lines, regardless of a cancerous or non-cancerous nature.

In conclusion, in this study, we provide evidence that the expression of BORIS does not change during differentiation of pluripotent P19 cells. Moreover, Boris is expressed at approximately the same level in cancer and non-cancer cell lines. Thus, the expression of BORIS may not be limited to cancerous and pluripotent cells.
Figure 5. BORIS immunostaining of P19 cells during RA-induced differentiation

Staining of BORIS protein in undifferentiated P19 cells (A), EB4 trypsinized into single cells (B), intact EB4 (C), and EB-D4 (D and E). Scale bars, 100 μm (A–C and E) or 250 μm (D).

Figure 6. Expression analysis of BORIS during RA-induced differentiation of P19 cells

FCM was used to identify the percentage of BORIS-positive cells in undifferentiated P19 (A; 73.7%) and EB-D4 (B; 74%) cells. Colored peaks show BORIS-positive cells, while white peaks represent negative controls (fluorescent signals obtained with the secondary antibody only).

Figure 7. Expression of Boris mRNA analyzed by RT-qPCR and normalized to L37

Data are represented as fold change relative to the highest Boris/L37 ratio (testis designated as 1.0). Two different RNA samples were used for each sample. Error bars indicate the standard deviation from two different experiments (A). Immunocytochemical detection of BORIS in mouse cell lines of 3T3 (B), STO (C), CT26 (D), N2A (E), and MEFs (F). Scale bars, 250 μm (B–E) or 100 μm (F).
Supplementary Data

Supplementary data are available at ABBS online.

Acknowledgements

The authors thank Dr Elena M. Pugacheva at National Institutes of Health (NIH) for generously providing BORIS expressing vectors, Dr Fatemeh B. Rassouli at Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran for the technical assistance, Dr Mohammad Mehdi Yaghoubi at International Center for Science, High Technology & Environmental Science, Kerman, Iran, for providing Neurofilament 200 antibody, and Dr Abdolreza Varaste at Mashhad University of Medical Sciences, Mashhad, Iran for laboratory equipment.

Funding

This work was supported by a grant from the Iranian Council of Biotechnology administered by Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran (grant number 56894, to H.D.).

References


